ACAD SEC Filings, Earnings & Splits

State Street Corporation filed a Schedule 13G disclosing a passive ownership stake of approximately 4.4% (7,650,889 shares) in Acadia Pharmaceuticals Inc. The filing is a routine passive institutional ownership disclosure under Rule 13d-1(b).

ACADIA Pharmaceuticals filed its quarterly 10-Q report for Q3 2026, disclosing financial results including revenue from Daybue and Nuplazid, R&D and SG&A expenses, and various license agreements. No single major corporate event is disclosed in the filing.

Acadia Pharmaceuticals filed an 8-K furnishing a press release announcing its financial results for the nine months ended September 30, 2026. The filing is a routine earnings results disclosure under Item 2.02.

Elizabeth H.Z. Thompson, Ph.D., Executive Vice President and Head of Research and Development of Acadia Pharmaceuticals, retired from her role and ceased being an employee effective October 23, 2026. She will remain as a limited consultant through December 31, 2026, while the company searches for her replacement.

Acadia Pharmaceuticals announced Phase 2 topline results for remlifanserin in Alzheimer's disease psychosis, showing positive efficacy trends and a favorable safety profile, and plans to continue Phase 3 studies.

Acadia Pharmaceuticals announced that the U.S. District Court for the Southern District of California preliminarily approved a settlement of a stockholder derivative action, requiring the company to publish a notice and stipulation of settlement.